Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(02): 268-274
DOI: 10.1055/s-0042-1760315
Review Article

Imaging Recommendations for Diagnosis, Staging, and Management of Bladder and Urethral Malignancies

Jinita Majithia 
1   Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Gagan Prakash 
2   Department of Uro-Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
MH Thakur
1   Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Palak Popat
1   Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Nilesh Sable
1   Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Aparna Katdare
1   Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Suyash Kulkarni
3   Department of Radiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Daksh Chandra
4   Intervention Radiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Bladder cancer (BCa) is a leading cause of cancer worldwide with high incidence and mortality across all ages. Early diagnosis and treatment can lead to significantly improved survival rate and overall prognosis. Smoking is the biggest contributing factor for the development of BCa. Urothelial carcinoma is the most common histological subtype. Commonly implemented imaging techniques include computed tomography urography (CTU) and multiparametric magnetic resonance imaging (mpMRI). CTU is the investigation of choice for muscle invasive bladder cancer (MIBC) and is best utilized for local assessment and staging of larger and higher staged tumors, that is, T3b and T4. mpMRI encompasses T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging. It can differentiate ≤T1 and ≥T2 tumors based on the Vesicle Imaging-Reporting and Data System (VI-RADS) assessment as well as differentiate Ta from T1 tumors, and is useful in post-therapy response assessment of BCa. Positron emission tomography/computed tomography is used in selected patients of MIBC for metastatic evaluation, particularly those with deranged renal function. A synoptic reporting template should be used to have standardization of data. Primary urethral cancer (UCa) is a rare and aggressive malignancy, accounting for less than 1% of all malignancies. MRI is the investigation of choice for UCa.

Keywords

bladder cancer - radiology - staging - urethral cancer - urology


Publication History

Article published online:
04 May 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Accessed December 12, 2022, at: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf
  • 2 Three-Year Report of Population Based Cancer Registries 2012–2014. 2016. Incidence, Distribution, Trends in Incidence Rates and Projections of Burden of Cancer (Report of 27 PBCRs in India). Accessed December 12, 2022, at: http://www.ncdirindia.org/NCRP/all_ncrp_reports/pbcr_report_2012_2014/all_content/pdf_printed_version/preliminary_pages_printed.pdf
    Google Scholar
  • 3 SEER*Explorer. [(accessed on 13 January 2020)]; Accessed December 12, 2022, at: https://seer.cancer.gov/explorer/
    Google Scholar
  • 4 Al-Husseini MJ, Kunbaz A, Saad AM. et al. Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. BMC Cancer 2019; 19 (01) 46
    CrossrefPubMedGoogle Scholar
  • 5 Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci (Basel) 2020; 8 (01) 15
    Google Scholar
  • 6 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
    CrossrefPubMedGoogle Scholar
  • 7 Riegert-Johnson DL, Gleeson FC, Roberts M. et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8 (01) 6 DOI: 10.1186/1897-4287-8-6.
    CrossrefPubMedGoogle Scholar
  • 8 van der Post RS, Kiemeney LA, Ligtenberg MJL. et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010; 47 (07) 464-470
    CrossrefPubMedGoogle Scholar
  • 9 Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306 (07) 737-745
    CrossrefPubMedGoogle Scholar
  • 10 Chen HI, Liou SH, Loh CH, Uang SN, Yu YC, Shih TS. Bladder cancer screening and monitoring of 4,4′-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology 2005; 66 (02) 305-310
    CrossrefPubMedGoogle Scholar
  • 11 Marshall G, Ferreccio C, Yuan Y. et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007; 99 (12) 920-928
    CrossrefPubMedGoogle Scholar
  • 12 Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 2005; 174 (01) 107-110 , discussion 110–111
    CrossrefPubMedGoogle Scholar
  • 13 Zelefsky MJ, Housman DM, Pei X. et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 83 (03) 953-959
    CrossrefPubMedGoogle Scholar
  • 14 Verma S, Rajesh A, Prasad SR. et al. Urinary bladder cancer: role of MR imaging. Radiographics 2012; 32 (02) 371-387
    CrossrefPubMedGoogle Scholar
  • 15 Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of tumors of the urinary system and male genital organs-part B. Prostate and Bladder Tumors. Eur. Urol. 2016; 70: 106-119
    PubMedGoogle Scholar
  • 16 Lee CH, Tan CH, Faria SC, Kundra V. Role of imaging in the local staging of urothelial carcinoma of the bladder. AJR Am J Roentgenol 2017; 208 (06) 1193-1205
    CrossrefPubMedGoogle Scholar
  • 17 Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 2009; 3 (6, Suppl 4): S193-S198
    CrossrefPubMedGoogle Scholar
  • 18 Flaig TW, Spiess PE, Agarwal N. et al. Bladder cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020; 18 (03) 329-354
    CrossrefPubMedGoogle Scholar
  • 19 Sun M, Trinh Q-D. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am 2015; 29 (02) 205-218 , vii
    CrossrefPubMedGoogle Scholar
  • 20 Wolfman DJ, Marko J, Nikolaidis P. et al. Expert panel on urological imaging. ACR Appropriateness Criteria® Hematuria. J Am Coll Radiol 2020; 17 (5S): S138-S147
    CrossrefPubMedGoogle Scholar
  • 21 Trinh TW, Glazer DI, Sadow CA, Sahni VA, Geller NL, Silverman SG. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. Abdom Radiol (NY) 2018; 43 (03) 663-671
    CrossrefPubMedGoogle Scholar
  • 22 Mirmomen SM, Shinagare AB, Williams KE, Silverman SG, Malayeri AA. Preoperative imaging for locoregional staging of bladder cancer. Abdom Radiol (NY) 2019; 44 (12) 3843-3857
    CrossrefPubMedGoogle Scholar
  • 23 Galgano SJ, Porter KK, Burgan C, Rais-Bahrami S. The role of imaging in bladder cancer diagnosis and staging. Diagnostics (Basel) 2020; 10 (09) 703
    CrossrefPubMedGoogle Scholar
  • 24 Moon WK, Kim SH, Cho JM, Han MC. Calcified bladder tumors. CT features. Acta Radiol 1992; 33 (05) 440-443
    CrossrefPubMedGoogle Scholar
  • 25 Mossanen M, Chang SL, Kimm S, Sonpavde GP, Kibel AS. Current staging strategies for muscle-invasive bladder cancer and upper tract urothelial cell carcinoma. Urol Clin North Am 2018; 45 (02) 143-154
    CrossrefPubMedGoogle Scholar
  • 26 Pichler R, De Zordo T, Fritz J. et al. Pelvic lymph node staging by combined 18F-FDG-PET/CT imaging in bladder cancer prior to radical cystectomy. Clin Genitourin Cancer 2017; 15 (03) e387-e395
    CrossrefPubMedGoogle Scholar
  • 27 Cornelissen SWE, Veenboer PW, Wessels FJ, Meijer RP. Diagnostic accuracy of multiparametric MRI for local staging of bladder cancer: a systematic review and meta-analysis. Urology 2020; 145: 22-29
    CrossrefPubMedGoogle Scholar
  • 28 Gandhi N, Krishna S, Booth CM. et al. Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU Int 2018; 122 (05) 744-753
    CrossrefPubMedGoogle Scholar
  • 29 Panebianco V, Narumi Y, Altun E. et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system). Eur Urol 2018; 74 (03) 294-306
    CrossrefPubMedGoogle Scholar
  • 30 Caglic I, Panebianco V, Vargas HA. et al. MRI of bladder cancer: local and nodal staging. J Magn Reson Imaging 2020; 52 (03) 649-667
    CrossrefPubMedGoogle Scholar
  • 31 Takeuchi M, Sasaki S, Ito M. et al. Urinary bladder cancer: diffusion-weighted MR imaging–accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009; 251 (01) 112-121
    CrossrefPubMedGoogle Scholar
  • 32 Bryan RT, Liu W, Pirrie SJ. et al. Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: preliminary data from the BladderPath Study. Eur Urol 2021; 80 (01) 12-15
    CrossrefPubMedGoogle Scholar
  • 33 Yuan L, Li D, Mu D. et al. Combined T2 SPAIR, dynamic enhancement and DW imaging reliably detect T staging and grading of bladder cancer with 3.0T MRI. Front Oncol 2020; 10: 582532
    CrossrefPubMedGoogle Scholar
  • 34 Necchi A, Bandini M, Calareso G. et al. Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study. Eur Urol 2020; 77 (05) 636-643
    CrossrefPubMedGoogle Scholar
  • 35 Bidnur S, Savdie R, Black PC. Inhibiting immune checkpoints for the treatment of bladder cancer. Bladder Cancer 2016; 2 (01) 15-25
    CrossrefPubMedGoogle Scholar
  • 36 van der Pol CB, Sahni VA, Eberhardt SC. et al; Expert Panel on Urologic Imaging. ACR appropriateness criteria® pretreatment staging of muscle-invasive bladder cancer. J Am Coll Radiol 2018; 15 ( 5S): S150-S159
    CrossrefPubMedGoogle Scholar
  • 37 Witjes JA, Babjuk M, Bellmunt J. et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2020; 77 (02) 223-250
    CrossrefPubMedGoogle Scholar
  • 38 Soubra A, Hayward D, Dahm P. et al. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol 2016; 34 (09) 1229-1237
    CrossrefPubMedGoogle Scholar
  • 39 Girard A, Rouanne M, Taconet S. et al. Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. Eur Radiol 2019; 29 (08) 4286-4293
    CrossrefPubMedGoogle Scholar
  • 40 Chen R, Zhou X, Liu J, Huang G. Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. Eur J Nucl Med Mol Imaging 2019; 46 (04) 848-854
    CrossrefPubMedGoogle Scholar
  • 41 van de Putte EEF, Vegt E, Mertens LS. et al. FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy. Int Urol Nephrol 2017; 49 (09) 1585-1591
    CrossrefPubMedGoogle Scholar
  • 42 Zattoni F, Incerti E, Colicchia M. et al. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdom Radiol (NY) 2018; 43 (09) 2391-2399
    CrossrefPubMedGoogle Scholar
  • 43 Rosenkrantz AB, Friedman KP, Ponzo F. et al. Prospective pilot study to evaluate the incremental value of PET information in patients with bladder cancer undergoing 18F-FDG simultaneous PET/MRI. Clin Nucl Med 2017; 42 (01) e8-e15
    CrossrefPubMedGoogle Scholar
  • 44 Kim S-J, Koo PJ, Pak K, Kim I-J, Kim K. Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis. World J Urol 2018; 36 (03) 331-340
    CrossrefPubMedGoogle Scholar
  • 45 Loffroy R, Pottecher P, Cherblanc V. et al. Current role of transcatheter arterial embolization for bladder and prostate hemorrhage. Diagn Interv Imaging 2014; 95 (11) 1027-1034
    CrossrefPubMedGoogle Scholar
  • 46 Liu S, Zhang L, Zou L, Wen H, Ding Q, Jiang H. The feasibility and safety of cryoablation as an adjuvant therapy with transurethral resection of bladder tumor: a pilot study. Cryobiology 2016; 73 (02) 257-260
    CrossrefPubMedGoogle Scholar
  • 47 Liang Z, Fei Y, Lizhi N. et al. Percutaneous cryotherapy for metastatic bladder cancer: experience with 23 patients. Cryobiology 2014; 68 (01) 79-83
    CrossrefPubMedGoogle Scholar
  • 48 Barchetti G, Simone G, Ceravolo I. et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol 2019; 29 (10) 5498-5506
    CrossrefPubMedGoogle Scholar
  • 49 Ueno Y, Takeuchi M, Tamada T. et al. Diagnostic accuracy and interobserver agreement for the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer: a multireader validation study. Eur Urol 2019; 76 (01) 54-56
    CrossrefPubMedGoogle Scholar
  • 50 Del Giudice F, Barchetti G, De Berardinis E. et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020; 77 (01) 101-109
    CrossrefPubMedGoogle Scholar
  • 51 Panebianco V, De Berardinis E, Barchetti G. et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 2017; 27 (09) 3759-3766
    CrossrefPubMedGoogle Scholar
  • 52 Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: a systematic review and meta-analysis. Eur J Radiol 2017; 95: 46-55
    CrossrefPubMedGoogle Scholar
  • 53 Boorjian SA, Kim SP, Weight CJ, Cheville JC, Thapa P, Frank I. Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol 2011; 60 (06) 1266-1272
    CrossrefPubMedGoogle Scholar
  • 54 Gatta G, van der Zwan JM, Casali PG. et al; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47 (17) 2493-2511
    CrossrefPubMedGoogle Scholar
  • 55 Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology 2006; 68 (06) 1164-1168
    CrossrefPubMedGoogle Scholar
  • 56 Chaudhari VV, Patel MK, Douek M, Raman SS. MR imaging and US of female urethral and periurethral disease. Radiographics 2010; 30 (07) 1857-1874
    CrossrefPubMedGoogle Scholar
  • 57 Kawashima A, Sandler CM, Wasserman NF, LeRoy AJ, King Jr BF, Goldman SM. Imaging of urethral disease: a pictorial review. Radiographics 2004; 24 (Suppl. 01) S195-S216
    CrossrefPubMedGoogle Scholar